Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter "Meiji") announced that the company has concluded an investment agreement wi ...

Meiji Seika Pharma invests in MPM BioImpact's new technology and virology strategy to expand early-stage opportunities and enhance the global network.

Ultima Genomics, Inc., a developer of an ultra-high throughput next-generation sequencing (NGS) platform, today announced that its UG 100tm was selected as the sequencing platform to enable UK Biobank ...